Clinical Trial Results:
A PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY TO ASSESS SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF CC-220, ALONE AND IN COMBINATION WITH AN ANTI-CD20 MONOCLONAL ANTIBODY (MAB) IN SUBJECTS WITH RELAPSED OR REFRACTORY LYMPHOMAS
|
Summary
|
|
EudraCT number |
2020-000354-10 |
Trial protocol |
DE |
Global completion date |
|
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Dec 2025
|
First version publication date |
07 Dec 2025
|
Other versions |
|
Summary report(s) |
CC-220-NHL-001 Closeout CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.